Saint Louis University Researchers Identify a Biomarker for Severe Liver Disease in Infants
ST. LOUIS — In a new study, Saint Louis University School of Medicine researchers and colleagues have identified biomarkers in high-risk infants with alpha-1 antitrypsin deficiency (AATD). This is a condition that is life-threatening in some infants but very mild in others. For the first time, predicting which children need lifesaving intervention is possible.
This latest advance follows the discovery of the first possible treatment for adults with AATD by SLU scientists and a Takeda Inc. team in 2022, bringing us nearer to the day when liver transplants are no longer required to treat rare liver disease.
Jeffrey Teckman, M.D., professor of pediatrics and biochemistry and molecular biology, in his lab at the Doisy Research Center on April 11, 2023. Photo by Sarah Conroy.
The findings, which recently appeared in Gastro Hep Advances, suggest that circulating Z polymer levels serve as a biomarker for those with AATD who are likely to develop severe liver disease.
“These data will allow identification of a group of infants at high risk of severe disease soon after diagnosis,” said Jeffrey Teckman, M.D., professor of pediatrics and biochemistry and molecular biology at Saint Louis University.
Teckman is the paper's senior author. He is a leading authority on AATD, a genetic disease that affects one in 3,500 people and has over 100 variants, including ZZ genotypes that increase the risk for lung and liver disease in adults and children.
Symptoms may include shortness of breath and wheezing, repeated infections of the lungs, yellow skin, fatigue, cirrhosis, clinically evident portal hypertension (CEPH), liver failure and even death. Other than a liver transplant, Teckman says there is currently no treatment for AATD.
Scientists have made significant progress in developing new therapies for AATD in recent years, though none are yet approved. While many adult clinical trials enroll participants, none study infants or children. The newly identified biomarkers in infants will stimulate and accelerate future pediatric clinical trials associated with high-risk infants.
“Enrollment of children into trials can then be focused on this high-risk group, sparing many participants from needless trials and speeding the effective treatments to proof of efficacy and approval,” said Teckman, who is also director of pediatric gastroenterology and hepatology at SLU.
The data was collected by the Childhood Liver Disease Research Network (ChiLDReN), a National Institutes of Health (NIH)-supported consortium of pediatric tertiary care centers in North America.
Seventeen consortium centers collected data during the study period, focusing on pediatric liver diseases and aiming to describe the natural history and genetic and environmental modifiers of a group of metabolic-cholestatic liver diseases, including AATD. Researchers measured ZZ AAT serum polymer levels from prospectively collected samples from participants in the Longitudinal Observational Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) and compared their outcomes in the longitudinal database.
Keith Blomenkamp, senior research assistant in Jeffrey Teckman’s lab, co-authored the paper and is shown here at the Doisy Research Center on April 11, 2023. Photo by Sarah Conroy.
Teckman and his colleagues obtained data and samples to identify biomarkers predictive of severe AATD liver disease. They analyzed prospective AATD ChiLDReN data and serum samples from 251 individuals from 2007-2015 for outcomes and Z polymer levels. Researchers found that 58 of 251 had CEPH at enrollment, and 10 developed CEPH during follow-up. Higher Z AAT polymer levels were associated with existing CEPH. In infants without CEPH, higher polymer levels were related to future CEPH later in childhood, but total AAT was not predictive. In the first few months of life, gamma-glutamyl transpeptidase (GGT), an enzyme found throughout the body, particularly in the liver, was also significantly associated with future CEPH.
Teckman and his colleagues constructed a model identifying subjects at high risk of future CEPH by combining clinical GGT and polymer levels. High circulating Z polymer levels and high GGT early in life are associated with future CEPH in AATD.
Additional authors of the paper include Paula Buchanan, Ph.D., Department of Health and Clinical Outcomes Research, Saint Louis University School of Medicine; Keith Steven Blomenkamp, Departments of Pediatrics and Biochemistry and Molecular Biology, Saint Louis University School of Medicine, SSM Health Cardinal Glennon Children's Hospital; Keith Burling, Core Biochemical Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Nina Heyer-Chauhan, Ph.D., UCL Respiratory, Division of Medicine, University College London; and David A Lomas, Ph.D., UCL Respiratory, Division of Medicine, University College London.
Teckman is supported by the ChiLDReN: NIH: DK 62453 and UL1 TR002535 (University of Colorado Denver, Children’s Hospital Colorado, subcontracts), Alpha-1 Foundation, Saint Louis University Liver Center, Cardinal Glennon Children’s Hospital Foundation.
Lomas is supported by the Medical Research Council (UK) (MR/NO24842/1 and MR/V034243/1), the Alpha-1 Foundation (USA), Alpha-1 Awareness and the NIHR UCLH Biomedical Research Centre. He is an NIHR Senior Investigator. University of Michigan, Sample and Data Coordinating Center; NIH-DK062456 (collection and distribution of biosamples and data).
Latest Newslink
- SLU Hispanic Studies Professor Named Distinguished Visiting Professor in the Humanities at East Carolina UniversityAmy E. Wright, Ph.D., professor of Hispanic Studies at Saint Louis University, has been named the David Julian and Virginia Suther Whichard Distinguished Professor in the Humanities at East Carolina University. She will hold the visiting Whichard professorship in ECU’s Thomas Harriot College of Arts and Sciences for two years before returning to SLU.
- SLU, Maryville Team Up with Women in Cybersecurity to Close the Cyber Talent GapStudents from the Saint Louis University and Maryville University Women in Cybersecurity chapters are teaming up to address one of the nation's most critical challenges: the shortage of skilled professionals trained to combat escalating cybersecurity threats.
- SLU's Emerson Leadership Institute to Kick Off Speaker Series with Barry-Wehmiller's Bob ChapmanSaint Louis University’s Emerson Leadership Institute will host Bob Chapman, chairman of Barry-Wehmiller, as part of its Leadership Speaker Series on Monday, Nov. 3. The free event will include a fireside chat on dignity-based leadership with Jackson Nickerson, Ph.D., Edward Jones Dean of the Richard A. Chaifetz School of Business at SLU.
- SLU's Flying Billikens to Host Regional Event for National Intercollegiate Flying CompetitionThe Flying Billikens from the Oliver L. Parks Department of Aviation Science will host the 2025 National Intercollegiate Flying Association Competition's Region VI and VIII SAFECON event Oct. 13-18 at the St. Louis Downtown Airport.
- SLU Program in Physical Therapy Class of 2028 Celebrates White Coat CeremonyThe Saint Louis University Doctor of Physical Therapy (DPT) Class of 2028 recently celebrated its initiation into the professional phase of the program by hosting a white coat ceremony. The ceremony took place at Saint Francis Xavier College Church and celebrated more than 80 students advancing to the professional phase of the program.
- Saint Louis University Commits up to $1.4 Million for Teacher Education Through New StayTeachLead Scholarship ProgramThis week, Saint Louis University School of Education launched the StayTeachLead Scholarship Program, an initiative designed to strengthen the local teacher pipeline through direct partnerships with St. Louis area schools.
